Daily pill slashes 'bad' cholesterol levels by 60% in year-long trial

Merck’s investigational oral pill Enlicitide produced a mean LDL‑cholesterol reduction of ~58% at 24 weeks and about 55% at 52 weeks versus placebo in a randomized global trial of 303 adults with heterozygous familial hypercholesterolemia (59 sites, 17 countries); non‑HDL fell 52%, apolipoprotein B 48% and lipoprotein(a) ~25%, with similar adverse‑event rates to placebo and a 97% completion rate. The magnitude of lipid lowering suggests Enlicitide could offer a once‑daily oral alternative to injectable PCSK9 inhibitors, but the study measured surrogate lipid endpoints in HeFH patients on background therapy and was limited to one year, so cardiovascular outcome and long‑term safety data are still needed.

Analysis

The phase of global randomized trial reported that Merck’s oral agent Enlicitide produced a mean LDL‑cholesterol reduction of ~58% at 24 weeks and sustained ~55% at 52 weeks versus placebo in 303 adults with heterozygous familial hypercholesterolemia (HeFH) across 59 sites in 17 countries, with non‑HDL down ~52%, apolipoprotein B down ~48% and lipoprotein(a) down ~25%. Trial retention was high (97% completion) and adverse‑event rates were comparable to placebo, with mainly mild transient events, supporting a favorable short‑term tolerability signal for a once‑daily oral therapy that achieved magnitudes of lipid lowering similar to injectable PCSK9 inhibitors.

Key limitations constrain near‑term commercial and clinical impact: the study measured surrogate lipid endpoints rather than cardiovascular outcomes, enrolled only HeFH patients already on background lipid‑lowering therapy, and lasted one year so long‑term safety and efficacy in broader hypercholesterolemia populations remain unproven. Regulatory approvals and payer decisions will hinge on ongoing outcome trials and durability/safety data, and the potential to displace injectable PCSK9s depends on those results plus pricing and uptake considerations.

Market signaling is moderately positive for Merck (per sentiment score ~0.45) but overall market impact is assessed as modest (market_impact_score 0.35), implying an informational catalyst rather than an immediate transformational event until outcome and regulatory data arrive.

Key Decisions for Investors

• Consider establishing a modest, risk‑limited exposure to MRK to reflect the positive short‑term efficacy and tolerability signal, but avoid increasing core positions until cardiovascular outcome and long‑term safety data are reported
• Monitor upcoming outcome trial readouts, regulatory filings, and payer/pricing guidance closely, as these will determine commercial potential versus injectable PCSK9 inhibitors
• Use position sizing and hedges to limit downside from adverse longer‑term safety findings or regulatory delays, and reassess strategy if broader population or hard‑outcome benefits are demonstrated